Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Monsanto Stock Continues Climbing As Takeover May Happen

Published 07/19/2016, 01:44 AM
Updated 05/14/2017, 06:45 AM

Monsanto Company (NYSE:MON)

Monsanto has had an incredibly strong time in the market over the past few trading sessions, and the gains continue today. The gains we’ve seen recently revolve around one of the favorite topics among investors, a possible acquisition. Today, we’ll talk about the possible buy out, what we’re seeing in the market, and what we can expect to see from MON moving forward.

Bayer (DE:BAYGN) Really Wants MON

As mentioned above, Monsanto has had a great time in the market through the past few trading sessions. This is the result of an acquisition offer that has been increased. Bayer has been trying to buy the company for some time now. Previously, they offered $122 per share for a total buyout value of $62 billion. Nonetheless, MON declined the offer. The offer didn’t offer the premium the company wanted to see.

After the offer was declined, the story seemed to disappear. That is, until Bayer proved just how badly they want to acquire the company. The company recently offered an increased takeover bid, increasing their bid from $122 per share to $125 per share. In a statement, Bayer said that they believe that this offer fully captures the intrinsic value of MON.

What We’re Seeing In The Market Today

There are few things that have to potential to get investors quite as excited as news of possible mergers and acquisitions. As a result, we’ve seen strong gains in the value of the stock over the past few trading sessions. Today, Monsanto continues to climb in the market. Currently (3:39), the stock is trading at $106.36 per share after a gain of $2.91 per share or 2.81% thus far today.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

What We Can Expect To See Moving Forward

Moving forward, I have an incredibly bullish opinion of what we can expect to see from MON stock. First and foremost, let’s discuss the takeover bid. It is clear at this point that Bayer isn’t likely to let up. However, it’s important to consider the premium. The new offer is still well under the 30% top-of-the-line premium that many would expect from a buyout like this. Nonetheless, it is a great offer. With that said, the buyout plans are up in the air. No one really knows if MON is going to make the decision to sell. With that said, if I had to bet on a yay or nay, I would say nay. While the offer is improving, I don’t believe that it captures the true value of Monsanto. So, taking the offer, in my opinion, would be an injustice to shareholders.

At the end of the day, when we talk about MON, we’re talking about a company that has quite a bit going for it. The company is in the chemicals and biotechnology in agriculture industries. These industries are two that are doing very well at the moment. Not to mention, we’re not talking about the little guy here. Monsanto has built its name as a leader in the industry. They have a long list of products that sell well. Not to mention, they are incredibly profitable. Add all of this together with a great management team and a clear plan for growth moving forward, and we have a stock that’s likely to head up moving forward. All in all, I’m expecting to see further gains regardless of the possible acquisition.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.